Clindamycin Hydrochloride Capsules Recalled for cGMP Deviations
Preferred Pharmaceuticals, Inc. is voluntarily recalling Clindamycin Hydrochloride Capsules USP 300mg due to manufacturing process deviations. The recall affects 1190 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for manufacturing process deviations without reported illnesses or injuries. cGMP deviations represent a quality and control concern that could potentially lead to adverse health consequences, but the source text contains no evidence of actual harm, making this a precautionary recall classified as Moderate.
Plain-English summary
Preferred Pharmaceuticals, Inc. is voluntarily recalling Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, manufactured by Glenmark Pharmaceuticals Limited. The recall was initiated on April 18, 2025, due to Current Good Manufacturing Practice (cGMP) deviations.
The affected product is identified by NDC 68788-8685-03 and includes the following lot numbers: L0224T, K1824M, K0124N, J1624V, J0824O, I2424E, I1024O, A0925F, and L2324L, all with an expiration date of July 31, 2026. A total of 1190 bottles have been distributed nationwide in the United States.
Consumers who have purchased this medication should stop using it and contact their healthcare provider or pharmacist for guidance. The product should be returned to the pharmacy where it was dispensed or to the manufacturer for proper handling.
The recalled product
- Product
- Clindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark Pharmaceuticals Limited, NDC 68788-8685-03.
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug — Antibiotic
- Affected units
- 1,190
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- Lot #: L0224T
- K1824M
- K0124N
- J1624V
- J0824O
- I2424E
- I1024O
- A0925F
- L2324L
- Exp: 7/31/2026.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Preferred Pharmaceuticals, Inc.
See all →- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- HighIbuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-09-04
- HighDuloxetine Delayed-Release Capsules Recalled for Nitrosamine Impurity
FDA (Drugs) · 2024-05-29
- ModerateTizanidine tablets recalled nationwide for failed stability specifications
FDA (Drugs) · 2023-07-12
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19